Depending on the diagnosis and the mutational landscape of the tumor biopsies (e.g., BRAF mutation status), targeted therapy with mutant kinase inhibitors or immunotherapies with monoclonal antibodies against immune checkpoint inhibitors (e.g., anti‐CTLA4, anti‐PD‐1 antibodies) are currently being used for melanoma treatment [3]. The gene discussed is BRAF; the disease is melanoma.